Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | GUSB | P08236 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6570128 | 1.00 | KDM1A (0.58) | KDM1AMAPTKMT2APOLBTDP1 | |
| SCHEMBL685021 | 0.92 | KDM1A (0.61) | KDM1AMAPTKMT2APOLBTDP1 | |
| SCHEMBL20175461 | 0.90 | SIRT1 (0.64) | KDM1AMAPTKMT2APOLBTDP1 | |
| SCHEMBL6569257 | 0.88 | PIK3CG (0.69) | KDM1AMAPTKMT2APOLBTDP1 | |
| SCHEMBL684997 | 0.88 | PIK3CG (0.69) | KDM1AMAPTKMT2APOLBTDP1 | |
| SCHEMBL6569253 | 0.88 | PIK3CG (0.69) | KDM1AMAPTKMT2APOLBTDP1 | |
| SCHEMBL684835 | 0.87 | KDM1A (0.72) | KDM1AMAPTKMT2APOLBTDP1 | |
| SCHEMBL6568355 | 0.85 | KDM1A (0.69) | KDM1AMAPTKMT2APOLBLMNA | |
| SCHEMBL6568358 | 0.85 | KDM1A (0.69) | KDM1AMAPTKMT2APOLBLMNA | |
| SCHEMBL6570169 | 0.85 | KDM1A (0.77) | KDM1AMAPTKMT2APOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110963-A1 | Novel hydrazones | ARPIDA AG (CH) | 2004-06-10 | — | — | US | claimed |
| US-20040110963-A1 | Novel hydrazones | ARPIDA AG (CH) | 2004-06-10 | — | — | US | disclosed |
| EP-1404644-A2 | NOVEL HYDRAZONES | Arpida AG, (CH) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002070464-A2 | HYDRAZONES AND THEIR THERAPEUTIC USE | ARPIDA AG (CH) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110963-A1 | Novel hydrazones | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO | KDM1A 2684/4885MAPT 3140/4885KMT2A 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.